Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — Merger or Acquisition (May 2023)
17 slides from Ironwood Pharmaceuticals's merger presentation, May 22, 2023
Slide 1: Creating Value for GI Patients and Shareholders
Creating Value for GI Patients and Shareholders Acquisition of VectivBio May 22, 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this communication may constitute “forward-looking statements”. Forward-looking statements may be typically identified by such words as “may,” “will,” “could,” “should,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,”
Slide 3: Ironwood Participants
Ironwood Participants • Tom McCourt Chief Executive Officer Mike Shetzline, M.D., Ph.D Chief Medical Officer • Sravan Emany Chief Financial Officer Andrew Davis Chief Business Officer 3
Slide 4: Acquisition of VectivBio advances Ironwood's GI leadership and creates value for patients and shareholders
Acquisition of VectivBio advances Ironwood’s GI leadership and creates value for patients and shareholders Advancing the treatment of GI diseases and redefining the standard of care for GI patients Apraglutide is a Leverages Ironwood’s $1B2 Apraglutide Peak Net Sales Potential; Potential Best-in-Cla
Slide 5: Strengthens GI pipeline with several near-term development milestones
Strengthens GI pipeline with several near-term development milestones to drive shareholder value Anticipated Discovery Preclinical Phase 1 Phase 2 Phase 3 Marketed Milestones / Catalysts IBS-C & CIC1 LINZESS PDUFA Date: June 14, 2023 Pediatric FC & IBS-C sNDA Filed; PDUFA Date for FC: June 14, 2023
Slide 6: Apraglutide: Potential Best-in-Class GLP-2 for SBS-IF
Apraglutide: Potential Best-in-Class GLP-2 for SBS-IF
Slide 7: Short Bowel Syndrome with Intestinal Failure is a condition with high unmet need
Short Bowel Syndrome with Intestinal Failure (SBS-IF) is a condition with high unmet need A severe condition that may require life-long parenteral support (PS)1 Significant Number of Adult Patients8 ~17k U.S. & Europe ~1k Japan Short Bowel Syndrome with Intestinal Failure (SBS-IF) anatomical subtype
Slide 8: Apraglutide: poised to establish a new standard of care for SBS-IF
Apraglutide: poised to establish a new standard of care for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Apraglutide Target Product Profile* Enabled by pharmacologic and developmental strategy Differentiated Novel Phase 3 Differentiated Pharmacology Design Dosing Designed for enhanced Desig
Slide 9: Leverages Ironwood's GI Capabilities and Success
Leverages Ironwood’s GI Capabilities and Success
Slide 10: Apraglutide has potential to achieve $1B in peak net sales
Apraglutide has potential to achieve $1B in peak net sales Apraglutide target product profile can enable market leadership position in SBS-IF (Stoma and CIC1) Potential Apraglutide Growth Drivers Expand use $1B+2 Improve outside the U.S. persistency Increase Gattex in 2022 utilization Net Sales ~$75
Slide 11: Apraglutide enhances Ironwood's GI portfolio
Apraglutide enhances Ironwood’s GI portfolio Apraglutide CNP-104 Indication / Adults with IBS-C and SBS-IF Primary Biliary Cholangitis Disease Area Chronic Idiopathic Constipation (Stoma & Colon-In-Continuity) (PBC) Addressable 1 2 3 40M adults (US) ~9K (US) ~130K patients (US) market Gastroenterolo
Slide 12: Enhances compelling financial profile
Enhances compelling financial profile
Slide 13: Apraglutide and CNP-104 have the potential to extend Ironwood's growth horizon through the 2030s
Apraglutide and CNP-104 have the potential to extend Ironwood’s growth horizon through the 2030s Ironwood Today Pro Forma Ironwood Long Term (Assuming Approval) $1.5B+2 peak sales potential ~$1.0B2 $0.4B1 YE 2022 YE 2028 Late 2030s LINZESS (2029 LOE) Apraglutide CNP-104 13 1 2022 Ironwood revenue..
Slide 14: Acquisition of VectivBio positions Ironwood for long-term growth
Acquisition of VectivBio positions Ironwood for long-term growth to drive shareholder value Transaction Overview • Holders of VECT will be entitled to receive $17.00/share • Total transaction aggregate consideration of ~$1B, net of VectivBio cash and debt • Ironwood expects to finance the acquisitio
Slide 15: Acquisition of VectivBio enhances and extends Ironwood's compelling financial profile
Acquisition of VectivBio enhances and extends Ironwood’s compelling financial profile Near-Term Financial Impact • If approved, potential apraglutide SBS-IF commercial launch in 2025 • Ironwood expects to generate greater than $175 million in operating cash flows per year on a pro forma basis ahead
Slide 16: Acquisition of VectivBio advances Ironwood's GI leadership and creates value
Acquisition of VectivBio advances Ironwood’s GI leadership and creates value for patients and shareholders Advancing the treatment of GI diseases and redefining the standard of care for GI patients Apraglutide is a Leverages Ironwood’s $1B2 Apraglutide Peak Net Sales Potential; Potential Best-in-Cla
Slide 17: Additional Information and Where to Find It
Additional Information and Where to Find It The description contained herein is for informational purposes only and is not a recommendation, an offer to buy or the solicitation of an offer to sell any shares of VectivBio’s ordinary shares. The tender offer for VectivBio’s outstanding ordinary shares
Ironwood Pharmaceuticals — Merger or Acquisition (May 2023) on 6ix